Printer Friendly

A NEW treatment for men [...].

A NEW treatment for men with prostate problems could reduce the need for surgery and halt disease progression, its manufacturers said.

A four-year study by GlaxoSmithKline (GSK) into a combined treatment using two drugs found results were better than using the individual drugs - Avodart or Tamsulosin -alone.

Almost half of men over 50 have the condition benign prostate hyperplasia (BPH), an enlarged prostate, which in itself is not life-threatening, but can lead to complications and the need for surgery.

BPH is associated with incontinence and the urge to urinate more frequently and can impair quality of life. In the GSK study, some men with moderate-to-severe symptoms were given the dual treatment CombAT, while others received just Avodart or Tamsulosin. After four years, those who had the combined treatment reported fewer symptoms than those on single doses.

Dr Mark Embleton, Urology Consultant at the University College of London, said: "As a treating clinician, the CombAT study results are very encouraging as they show that BPH can be effectively treated using combination therapy, reducing the risk of disease progression and surgery related to this disease. "Disease progression often leads to more severe symptoms and can cause AUR, a sudden inability to pass urine, which is always painful and involves treatment with catherisation or prostate surgery."
COPYRIGHT 2009 MGN Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Features
Publication:Evening Chronicle (Newcastle, England)
Date:Oct 19, 2009
Words:213
Previous Article:A TOP German cancer specialist [...].
Next Article:Health workers at head of vaccine queue.


Related Articles
Animal activists draw ire of milk industry.
Over 800 urologists to attend Malaysia meet.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters